Charles Schwab Investment Management Inc Supernus Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$429 Billion
Q1 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 592,646 shares of SUPN stock, worth $16.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

592,646

Previous 555,930 6.6%

Holding current value

$16.1 Million

Previous $16.1 Million 25.65%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$27.11 - $35.17 $995,370 - $1.29 Million	36,716 Added 6.6%	592,646 $20.2 Million
Q4 2023 Feb 06, 2024	BUY	$22.72 - $29.68 $560,820 - $732,621	24,684 Added 4.65%	555,930 $16.1 Million
Q3 2023 Nov 08, 2023	SELL	$27.57 - $32.91 $310,493 - $370,632	-11,262 Reduced 2.08%	531,246 $14.6 Million
Q2 2023 Aug 09, 2023	BUY	$29.91 - $38.73 $978,116 - $1.27 Million	32,702 Added 6.41%	542,508 $16.3 Million
Q1 2023 May 11, 2023	BUY	$34.93 - $42.03 $82,260 - $98,980	2,355 Added 0.46%	509,806 $18.5 Million

Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $1.23 Million - $1.5 Million	39,677 Added 8.48%	507,451 $18.1 Million
Q3 2022 Nov 14, 2022	BUY	$28.79 - $35.41 $1.1 Million - $1.36 Million	38,323 Added 8.92%	467,774 $15.8 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $687,988 - $930,264	27,161 Added 6.75%	429,451 $12.4 Million
Q1 2022 May 13, 2022	BUY	$28.51 - $32.9 $946,474 - $1.09 Million	33,198 Added 8.99%	402,290 $13 Million
Q4 2021 Feb 11, 2022	BUY	$26.37 - $34.22 $186,884 - $242,517	7,087 Added 1.96%	369,092 $10.8 Million
Q3 2021 Nov 16, 2021	SELL	$23.54 - $31.39 $1.33 Million - $1.77 Million	-56,535 Reduced 13.51%	362,005 $9.66 Million
Q2 2021 Aug 16, 2021	SELL	$26.72 - $33.19 $865,434 - $1.07 Million	-32,389 Reduced 7.18%	418,540 $12.9 Million
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $276,082 - $359,536	11,432 Added 2.6%	450,929 $11.8 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $127,740 - $186,270	-7,217 Reduced 1.62%	439,497 $11.1 Million
Q3 2020 Nov 13, 2020	BUY	$20.2 - $25.05 $2.09 Million - $2.6 Million	103,632 Added 30.21%	446,714 $9.31 Million
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $392,010 - $570,926	22,938 Added 7.16%	343,082 $8.15 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $1.23 Million - $2.1 Million	-85,224 Reduced 21.02%	320,144 $5.76 Million
Q4 2019 Feb 07, 2020	BUY	$19.93 - $29.13 $125,957 - $184,101	6,320 Added 1.58%	405,368 $9.62 Million
Q3 2019 Nov 08, 2019	BUY	$25.47 - $33.37 $1.08 Million - $1.41 Million	42,324 Added 11.86%	399,048 $11 Million
Q2 2019 Aug 09, 2019	BUY	$29.96 - $38.87 $799,542 - $1.04 Million	26,687 Added 8.09%	356,724 $11.8 Million
Q1 2019 May 14, 2019	BUY	$32.77 - $41.99 $404,676 - $518,534	12,349 Added 3.89%	330,037 $11.6 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $187,784 - $301,466	6,089 Added 1.95%	317,688 $10.6 Million
Q3 2018 Nov 13, 2018	BUY	$42.7 - $56.55 $1.01 Million - $1.34 Million	23,662 Added 8.22%	311,599 $15.7 Million
Q2 2018 Aug 08, 2018	SELL	$44.1 - $59.85 $1.26 Million - $1.71 Million	-28,509 Reduced 9.01%	287,937 $17.2 Million
Q1 2018 May 07, 2018	BUY	$37.15 - $46.9 $1.13 Million - $1.43 Million	30,443 Added 10.64%	316,446 $14.5 Million
Q4 2017 Jan 17, 2018	BUY	$36.4 - $42.6 $1.77 Million - $2.08 Million	48,732 Added 20.54%	286,003 $11.4 Million
Q3 2017 Nov 13, 2017	BUY	$36.75 - $49.65 $8.72 Million - $11.8 Million	237,271	237,271 $9.49 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.45B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Supernus Pharmaceuticals, Inc. Transaction History